



## Stem Cell Therapies in the Fight of Amyotrophic Lateral Sclerosis

Guest Editor:

**Dr. Maria Gaitanou**

Laboratory of Cellular and  
Molecular Neurobiology-Stem  
Cells, Department of  
Neurobiology, Hellenic Pasteur  
Institute, 115 21 Athens, Greece

Deadline for manuscript  
submissions:

**closed (25 May 2024)**

### Message from the Guest Editor

Amyotrophic lateral sclerosis (ALS) is a progressive, incurable, fatal neurodegenerative disease, the pathogenesis of which still remains elusive. Stem cell therapy for fighting ALS is a hot topic in basic and clinical research. Stem cell approaches are applied in ALS basic research using animal models of the disease, as well as in clinical trials of ALS patients. Stem cell therapies mainly aim to provide neuroprotection and survival of damaged motor neurons. Stem cells also provide immunomodulation, secrete growth factors, and serve to produce supporting cells, such as astrocytes and oligodendrocytes, or interneurons, which may provide a supportive environment to the vulnerable MNs. In this Special Issue, our scope is to present a comprehensive collection of research articles, data reports, and reviews contributed by leading experts in the ALS research field.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)